Spyre Therapeutics logo

Spyre TherapeuticsNASDAQ: SYRE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 April 2016

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.05 B
-3%vs. 3y high
81%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
93%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 107 min ago
$34.90+$7.00(+25.09%)

Dividend

No data over the past 3 years
$4.00 M$2.63 M

Analysts recommendations

Institutional Ownership

SYRE Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
accesswire.com19 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
prnewswire.com18 November 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing
prnewswire.com12 November 2024 Sentiment: POSITIVE

SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class SPY001 pharmacokinetics exceeded expectations with a ~4-fold increase relative to vedolizumab, supporting potential Q6M maintenance dosing with a single subcutaneous (SC) injection Planned Phase 2 induction regimen targets drug concentrations in quartile 4 of vedolizumab's exposure-response relationship, which has the potential to increase or accelerate efficacy Single, lowest dose of SPY001 led to complete saturation of α4β7 receptors through Week 12 (longest follow-up available for pharmacodynamic data) Company plans to initiate a platform Phase 2 trial in mid-2025 that will include SPY001, followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, providing three optimized monotherapy readouts and three potentially paradigm-changing combination readouts under an efficient single master protocol Management will host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass.

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
prnewswire.com11 November 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Nov. 11, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced it will report interim results from the Phase 1 SPY001 healthy volunteer trial on Tuesday, November 12, 2024.

Spyre Therapeutics Announces Grants of Inducement Awards
prnewswire.com01 November 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 90,000 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
prnewswire.com14 October 2024 Sentiment: POSITIVE

SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating robust preclinical activity including comparable potency and a greater than three-fold extension in half-life in NHPs relative to risankizumab1. Spyre portfolio now uniquely includes extended half-life molecules targeting α4β7, TL1A, and IL-23 with potential Q8W-Q12W maintenance dosing.

Spyre Therapeutics Announces Grants of Inducement Awards
prnewswire.com04 October 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Oct. 4, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of (i) stock options to purchase 400,000 shares of common stock of Spyre to Dr. Sheldon Sloan in connection with his appointment as Chief Medical Officer and (ii) stock options to purchase an aggregate of 129,000 shares of common stock of Spyre to four non-executive employees, in each case, as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
prnewswire.com01 October 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D.

Spyre Therapeutics to Participate in Upcoming Investor Conference
prnewswire.com10 September 2024 Sentiment: POSITIVE

WALTHAM, Mass. , Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit.

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
prnewswire.com07 August 2024 Sentiment: POSITIVE

Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities, and restricted cash as of June 30, 2024, with expected runway well into 2027, through multiple clinical readouts WALTHAM, Mass. , Aug. 7, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced its second quarter 2024 financial results and provided program and corporate updates.

What type of business is Spyre Therapeutics?

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

What sector is Spyre Therapeutics in?

Spyre Therapeutics is in the Healthcare sector

What industry is Spyre Therapeutics in?

Spyre Therapeutics is in the Biotechnology industry

What country is Spyre Therapeutics from?

Spyre Therapeutics is headquartered in United States

When did Spyre Therapeutics go public?

Spyre Therapeutics initial public offering (IPO) was on 07 April 2016

What is Spyre Therapeutics website?

https://www.spyre.com

Is Spyre Therapeutics in the S&P 500?

No, Spyre Therapeutics is not included in the S&P 500 index

Is Spyre Therapeutics in the NASDAQ 100?

No, Spyre Therapeutics is not included in the NASDAQ 100 index

Is Spyre Therapeutics in the Dow Jones?

No, Spyre Therapeutics is not included in the Dow Jones index

When was Spyre Therapeutics the previous earnings report?

No data

When does Spyre Therapeutics earnings report?

The next expected earnings date for Spyre Therapeutics is 28 February 2025